Sander J W, Trevisol-Bittencourt P C, Hart Y M, Shorvon S D
Institute of Neurology, National Hospital for Nervous Diseases, London, United Kingdom.
J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1008-10. doi: 10.1136/jnnp.53.11.1008.
The effects of the addition of Vigabatrin, a new anti-epileptic drug, to the therapy of 128 patients with severe medically refractory epilepsy is reported. Forty two (33%) of patients experienced side effects, which were predominantly neurotropic. In 28 (22%), the drug was withdrawn because of these side effects. The commonest side effects were drowsiness and behavioural change. The remaining 100 patients were followed for a mean of 30 weeks (range 12-75). Forty one of these patients showed a marked improvement in seizure frequency (a 50% or more reduction when compared with the pre-trial period), and nine (7%) were rendered seizure free. Apparent tolerance to the effects of the drug were noted in five patients. An exacerbation of seizures may occur if the drug is withdrawn too quickly. Vigabatrin appears to be a promising new anti-epileptic drug.
报告了将新型抗癫痫药物vigabatrin添加到128例严重药物难治性癫痫患者治疗中的效果。42例（33%）患者出现副作用，主要为神经毒性。28例（22%）患者因这些副作用停药。最常见的副作用是嗜睡和行为改变。其余100例患者平均随访30周（范围12 - 75周）。其中41例患者癫痫发作频率显著改善（与试验前期相比降低50%或更多），9例（7%）实现无癫痫发作。5例患者出现对药物作用的明显耐受性。如果停药过快，可能会出现癫痫发作加剧。Vigabatrin似乎是一种有前景的新型抗癫痫药物。
